Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 5, 2010, Pages 555-570

  Tengstrand, Elizabeth A ^a   Miwa, Gerald T ^a   Hsieh, Frank Y ^a  

^a Nextcea Inc   (United States)

Author keywords

Biomarker; Bis(monoacylglycerol)phosphate; Kidney toxicity; Lysobisphosphatidic acid; Myopathy; Phospholipid; Phospholipidosis; QT prolongation; Safety evaluation; Toxicology

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMIODARONE; ANTIMALARIAL AGENT; AZITHROMYCIN; BIOLOGICAL MARKER; CHLOROQUINE; CHLORPROMAZINE; ERYTHROMYCIN; FLUOXETINE; GENTAMICIN; HALOPERIDOL; IMIPRAMINE; LYSOBISPHOSPHATIDIC ACID; PENTAMIDINE; PREDNISONE; TELITHROMYCIN; UNCLASSIFIED DRUG;

BLOOD CELL; CELL FUNCTION; CYTOTOXICITY; ELECTRON MICROSCOPY; GRAM NEGATIVE INFECTION; HISTOPATHOLOGY; HUMAN; LIPIDOSIS; MYASTHENIA LIKE SYNDROME; MYOPATHY; NEPHROTOXICITY; NIEMANN PICK DISEASE; NONHUMAN; QT PROLONGATION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE SECTION; URINE SEDIMENT;

ANIMALS; BIOLOGICAL MARKERS; DRUG DESIGN; HUMANS; LIPIDOSES; LONG QT SYNDROME; LYSOPHOSPHOLIPIDS; MONOGLYCERIDES; NIEMANN-PICK DISEASE, TYPE C; PHARMACEUTICAL PREPARATIONS; PHOSPHOLIPIDS; RISK ASSESSMENT; TIME FACTORS;

EID: 77951288434     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425251003601961     Document Type: Review

References (109)

1. Schmitz G, Müller G. Structure and function of lamellar bodies, lipid-protein complexes involved in storage and secretion of cellular lipids. J Lipid Res 1991;32:1539-1570
2. DiAugustine RP. Lung concentric laminar organelle: hydrolase activity and compositional analysis. J Biol Chem 1974;249(2):584-593
3. Koenig H, Goldstone A, Blume G, Lu CY. Testosterone-mediated sexual dimorphism of mitochondria and lysosomes in mouse kidney proximal tubules. Science 1980;209(4460):1023-1026 (Pubitemid 10014877)
4. Sorokin SP. A morphologic and cytochemical study on the great alveolar cell. J Histochem Cytochem 1967;14(12):884-897
5. Anderson N, Borlak J. Drug-induced phospholipidosis. FEBS Lett 2006;580:5533-5540 (Pubitemid 44465910)
6. Reasor MJ, Hastings KL, Ulrich RG. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf 2006; 5(4):567-583 (Pubitemid 44468453)
7. Nonoyama T, Fukuda R. Drug induced phospholipidosis pathological aspects and its prediction. J Toxicol Pathol 2008;21:9-24
8. Shaikh NA, Downar E, Butany J. Amiodarone- an inhibitor of phospholipase activity: a comparative study of the inhibitory effects of amiodarone, chloroquine, and chlorpromazaine. Mol Cell Biochem 1987;76:163-172 (Pubitemid 17123264)
9. Jones CJP, Salisbury RS, Jayson MIV. The presence of abnormal lysosomes in lymphocytes and neutrophils during chloroquine therapy: a quantitative ultrastructural study. Ann Rheumatic Dis 1984;43:710-715
10. Mandal AK, Saklayen MG, Taylor CA, et al. An electron microscopy study of urinary sediment: relationship between myeloid body excretion and gentamicin toxicity in the rat. Ren Fail 1991;13(4):259-266
11. Katz SM, Sufian S, Matsumoto T. Urinary myelin figures in gentamicin nephrotoxicity. Am J Clin Pathol 1979;72(4):621-624 (Pubitemid 10247864)
12. Josepovitz C, Levine R, Lane B, et al. Contrasting effects of gentamicin and mercuric chloride on urinary excretion of enzymes and phospholipids in the rat. Lab Invest 1985;52(4):375-386 (Pubitemid 15056795)
13. Lüllmann H, Lüllman-Rauch R, Wassermann O. Lipidosis induced by amphiphilic catonic drugs. Biochem Pharmacol 1978;27:1103-1108 (Pubitemid 8393243)
14. Hammond TG, Majewski RR, Kaysen JH, et al. Gentamicin inhibits rat renal cortical homotypic endosomal fusion: role of megalin. Am J Physiol Renal Physiol 1997;272:F117-23 (Pubitemid 27382287)
15. Feldman S, Wang MY, Kaloyanides J. Aminoglycosides induce a phospholipidosis in the renal cortex of the rat: an early manifestation of nephrotoxicity. J Pharmacol Exp Ther 1982;220(3):514-520 (Pubitemid 12152161)
16. Josepovitz C, Farruggella T, Levine R, et al. Effect of netilmicin on the phospholipid composition of subcellular fractions of rat renal cortex. J Pharmacol Exp Ther 1985;235(3):810-819 (Pubitemid 16210752)
17. Sawada H, Takami K, Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci 2005;83(2):282-292 (Pubitemid 40227898)
18. Hutchinson TH, Mahshid Y, Jonsson R, et al. Proteomic analysis of phospholipidosis in citalopram treated U937 cells--support for the cholesterol biosynthesis hypothesis. Toxicol In Vitro 2008;22(5):1198-1204
19. Ikeda K, Hirayama M, Hirota Y, et al. Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor mediated targeting of lysosomal enzymes. Biochem Biophys Res Commun 2008;377:268-274
20. Kornfeld S. Trafficking of lysosomal enzymes. FASEB J 1987;1:462-468 (Pubitemid 18012081)
21. Morissette G, Ammoury A, Rusu D, et al. Intracellular sequestration of amiodarone: role of vacuolar ATPase and macroautophagic transition of the resulting vacuolar cytopathology. Br J Pharmacol 2009;157:1531-1540
22. Jahreiss L, Renna M, Bittman R, et al. 1-O-Hexadecyl-2-O-methyl-3-O- (2¢-acetamido-2¢-deoxy- D-glucopyranosyl)-sn-glycerol (Gln) induces cell death with more autophagosomes which is autophagy-independent. Autophagy 2009;5(6):835-846
23. De Duve C, De Barsy T, Poole B, et al. Lysomotrophic agents. Biochem Pharmacol 1974;23:2495-2531
24. FDA, FDA Projects in Scientific Priority Areas, March 2009. Available from: http://www.fda.gov/downloads/ AdvisoryCommittees/ CommitteesMeetingMaterials/ ScienceBoardtotheFoodandDrug Administration/ UCM152329.pdf. [Last accessed 29 December 2009]
25. Warren CD, Alroy J. Morphological, biochemical and molecular biology approaches for the diagnosis of lysosomal storage diseases. J Vet Diagn Invest 2000;12:483-496
26. Liscum L. Niemann-Pick Type C mutations cause lipid traffic jam. Traffic 2000;1:218-225
27. Liscum L, Sturley SL. Intracellular trafficking of Niemann-Pick proteins 1 and 2: obligate components of subcellular lipid transport. Biochim Biophys Acta 2004;1685:22-27 (Pubitemid 39328089)
28. Maxfield FR, Tabas I. Role of cholesterol and lipid organization in disease. Nature 2005;438:612-621 (Pubitemid 41740565)
29. Cheruku SR, Xu Z, Dutia R, et al. Mechanism of cholesterol transfer from the Niemann-Pick type C2 protein to model membranes supports a role in lysosomal cholesterol transport. J Biol Chem 2006;281(42):31594-31604 (Pubitemid 46041425)
30. Pacheco CD, Lieberman AP. The pathogenesis of Niemann-Pick type C disease: a role for autophagy? Expert Rev Mol Med 2008;10(26):1-14
31. Jenkins RW, Canals D, Hannun YA. Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal 2009;21:836-846
32. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009;29:431-438
33. Rouser G, Kritchevsky G, Yamamoto A, et al. Accumulation of glycerolphospholipid in classical Niemann-Pick disease. Lipids 1968;3(3):287-290
34. Harder A, Widjaja F, Debuch H. Studies on lipids from liver and spleen of a child (O.L.) with Niemann-Pick's disease type C. J Clin Chem Clin Biochem 1984;22(2):199-201 (Pubitemid 14157686)
35. Vanier MT, Pentchev P, Rodriguez-Lafrasse C, Rousson R. Niemann-Pick disease type C: an update. J Inherit Metab Dis 1991;14:580-595
36. Kolter T, Sandhoff K. Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. Annu Rev Cell Dev Biol 2005;21:81-103 (Pubitemid 41740628)
37. Bowley M, Cooling J, Burditt S, Brindley DN. The effects of amphiphilic cationic drugs and inorganic cations on the activity of phosphatidate phosphohydrolase. Biochem J 1977;165:447-454 (Pubitemid 8165049)
38. Ide H, Nakazawa Y. Effect of chlorpromazine on the cytoplasmic phosphatidate phosphohydrolase in rat liver. Biochem Pharmacol 1980;29:789-793 (Pubitemid 10174238)
39. Tyeryar KR, Vongtau HOU, Undieh AS. Diverse antidepressants increase CDP-diacyglycerol production and phosphatidylinositide resynthesis in depression-relevant regions of the rat brain. BMC Neurosci 2008;9:12
40. Reaves BJ, Row PE, Bright NA, et al. Loss of cation-independent mannose 6-phosphate receptor expression promotes the accumulation of lysobisphosphatidic acid in multilamellar bodies. J Cell Sci 2000;113:4099-4108
41. Kobayashi T, Stang E, Fang KS, et al. A lipid associated with the antiphospholipid syndrome regulates endosome structure and function. Nature 1998;392:193-197 (Pubitemid 28162794)
42. Pappu A, Hostetler KY. Effect of cationic amphiphilic drugs on the hydrolysis of acidic and neutral phospholipids by liver lysosomal phospholipase A. Biochem Pharmacol 1984;33(10):1639-1644 (Pubitemid 14147790)
43. Matsuzawa Y, Hostetler KY. Inhibition of lysosomal phospholipase A and phospholipase C by chloroquine and 4,4¢bis(diethylaminoethoxy)alpha, beta-diethyldiphenylethane. Journal of Biological Chemistry 1980;255(11):5190- 5194 (Pubitemid 10015837)
44. Joshi UM, Rao P, Kodavanti S, et al. Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: relevance to phospholipidosis. Biochim Biophys Acta 1989;1004:309-320 (Pubitemid 19216469)
45. Zwahlen R, Richardson BP, Hauser RE. The production and elimination of myeloid bodies by cultured pancreatic islet cells. J Ultrastructure Res 1979; 67(3):340-356 (Pubitemid 9252786)
46. Schmitz G, Grandl M. Endolysosomal phospholipidosis and cytosolic lipid droplet storage and release in macrophages. Biochim Biophys Acta 2008, doi:10.1016/j.bbalip.2008.12.007
47. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42
48. Berridge BR, Chatman LA, Odin M, et al. Letter to the editor. Toxicol Pathol 2007;35:325 (Pubitemid 46393076)
49. Willard J. FDA phospholipidosis working group preliminary results and developing opinions. Presented at the Society of Toxicology Pathology (STP) Continuing Education Course on Drug-Induced Phospholipidosis; June 2008
50. Chatman LA, Morton D, Johnson TO, Anway SD. A strategy for risk management of drug-induced phospholipidosis. Toxicol Pathol 2009;37:997-1005
51. Antonini JM, McCloud CM, Reasor MJ. Acute silica toxicity: attenuation by amiodarone induced pulmonary toxicity. Environ Health Perspect 1994;102:372-378
52. Blake TL, DiMatteo M, Antonini JM, et al. Subchronic pulmonary inflammation and fibrosis induced by silica in rats are attenuated by amiodarone. Exp Lung Res 1996;22(1):113-131
53. Hastings CE, DeNicola DB, Rebar AH, et al. The effect of chlorphentermine pretreatment on the toxicity of nitrogen dioxide in mice. Fundam Appl Toxicol 1987;9:69-81
54. Hruban Z. Pulmonary and generalized lysosomal storage induced by amphiphilic drugs. Environ Health Perspect 1984;55:53-76 (Pubitemid 14094798)
55. Laurent G, Kishore BK, Tulkens PM. Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. Biochem Pharmacol 1990;40(11):2383-2392
56. Reasor MJ, Kacew S. Drug-induced phospholipidosis: are there functional consequences? Exp Biol Med 2001;226(9):825-830 (Pubitemid 34053231)
57. Matsuzawa Y, Yamamoto A, Adachi S, et al. Studies on drug-induced lipidosis. VIII. Correlation between drug accumulation and acidic phospholipids. J Biochem 1977;82(5):1369-1377 (Pubitemid 8221879)
58. Yamamoto A, Adachi S, Kitani T, et al. Drug-induced lipidosis in human cases and in animal experiments: accumulation of an acidic glycerophospholipid. J Biochem 1971;69(3):613-615
59. Yamamoto A, Adachi S, Ishikawa K, et al. Studies on drug-induced lipidosis: III. Lipid composition of the liver and some other tissues in clinical cases of "Niemann-Pick-like-syndrome" induced by 4,4¢-diethylaminoethyoxyhexesterol. J Biochem 1971;70(5):775-784
60. Yamamoto A, Adachi S, Matsuzawa Y, et al. Studies on drug- induced lipidosis: VII. Effects of bis-beta-diethyl-aminoethylether of hexestrol, chloroquine, homochlorocyclizine, prenylamine, and diazacholesterol on the lipid composition of rat liver and kidney. Lipids 1976;11(8):616-622
61. Mortuza GB, Neville WA, Delaney J, et al. Characterization of a potential biomarker of phospholipidosis from amiodarone treated rats. Biochim Biophys Acta 2003;1631:136-146 (Pubitemid 36287509)
62. Cox JW, Ulrich JW, Wynalda MA, et al. Reversible, hepatic, lysosomal phospholipidosis in rat induced subchronic daily administration of trospectomycin sulfate. Biochem Pharmacol 1989;38(20):3535-3541
63. Poulos AP, Beckman K, Ellis DH, Pollard AC. Hepatic storage of bis (monoacylglycerol)phosphate without concomitant storage of sphingomyelin in a 72-year-old patient with a partial deficiency of sphingomyelinase. Clin Genet 1982;22:234-243 (Pubitemid 13209526)
64. Tengstrand-Baronas E, Lee JW, Alden C, Hsieh FH. Biomarkers to monitor drug-induced phospholipidosis. Toxicol Appl Pharmacol 2007;218:72-78 (Pubitemid 46026842)
65. Phillips JA, Papov VV, Stoltz JH, et al. Urinary LBPA tracks with onset and reversal of drug-induced phospholipidosis. Society of Toxicology Abstract 2009; Poster No. 724
66. Amidon B, Schmitt J, Thuren T, et al. Biosynthetic conversion of phosphatidylglycerol to sn-1:sn-1¢ bis (monoacylglycerol)phosphate in a macrophage-like cell line. Biochemistry 1995;34:5554-5560
67. Matsuo H, Chevallier J, Mayran N, et al. Role of LBPA and Alix in multivesicular liposome formation and endosome organization. Science 2004;303:531-534 (Pubitemid 38120852)
68. Huterer SJ, Wherrett JR. Formation of bis(monoacylglycero)phosphate by a macrophage transacylase. Biochem Biophys Acta 1989;1001:68-75
69. Matsuzawa Y, Poorthuis BJHM, Hostetler KJ. Mechanism of phosphatidylinositol stimulation of lysosomal bis(monoacylglyceryl)phosphate synthesis. J Biol Chem 1978;253:6650-6653 (Pubitemid 9060471)
70. Matsuzawa Y, Hostetler KY. Degradation of bis(monocylglycero)phosphate by an acid phosphodiesterase in rat liver lysosomes. J Biol Chem 1979;254(13):5997-6001
71. Wassall SR, Brzustowicz MR, Shaikh SR, et al. Order from disorder, corralling cholesterol with chaotic lipids, the role of polyunsaturated lipids in membrane raft formation. Chem Phys Lipids 2004;132:79-88
72. Schmid SL, Cullis PR. Membrane sorting: endosome marker is fat not fiction. Nature 1998;392:135-136
73. Xu Z, Farver W, Kodukula S, Storch J. Regulation of sterol transport between membranes and NPC2. Biochemistry 2008;47(42):11134-11143
74. Rouser G, Simon G, Kritchevsky G. Species variations in phospholipid class distribution of organs: I. kidney liver and spleen. Lipids 1969;4(6):599-606
75. Simon G. Species variations in phospholipid class distribution of organs: II heart and skeletal muscle. Lipids 1969;4(6):607-614
76. Martin WJ, Standing JE. Amiodarone pulmonary toxicity: biochemical evidence for a cellular phospholipidosis in the bronchoalveolar lavage of human subjects. J Pharmacol Exp Ther 1988;244(2):774-779
77. Gruenberg J. Lipids in endocytic membrane transport and sorting. Curr Opin Cell Biol 2003;15:382-388 (Pubitemid 36928039)
78. Mobius W, van Donselaar E, Ohno-Iwashita Y, et al. Recycling compartments and the internal vesicles of multivesicular bodies harbor most of the cholesterol found in the endocytic pathway. Traffic 2003;4:222-231 (Pubitemid 36665383)
79. Werth N, Schuette CG, Wilkening G, et al. Degradation of membrane-bound ganglioside GM2 by beta-hexosaminidase A. J Biol Chem 2001;276(16):12685-12690
80. Wilkening G, Linke T, Sandhoff K. Lysosomal degradation on vesicular membrane surfaces. Enhanced glucosylceramide degradation by lysosomal anionic lipids and activators. J Biol Chem 1998;273(46):30271-30278 (Pubitemid 28545494)
81. Wilkening G, Linke T, Uhlhorn-Dierks G, Sandhoff K. Degradation of membrane-bound galglioside GM1. Stimulation by bis (monoacylglycero)phosphate and the activator proteins SAP-B and GM2-AP. J Biol Chem 2000;275(46):35814- 35819
82. Linke T, Wilkening G, Sadeghlar F, et al. Interfacial regulation of acid ceramidase activity. Stimulation of ceramide degradation by lysosomal lipids and sphingolipid activator proteins. J Biol Chem 2001;276(8):5760-5768 (Pubitemid 37385729)
83. Chevallier J, Chamoun Z, Jiang G, et al. Lysobisphosphatidic acid controls endosomal cholesterol levels. J Biol Chem 2008;283(41):27871-27880
84. Pan S, Wang R, Zhou X, et al. Extracellular Alix regulates integrin-mediated cell adhesions and extracellular matrix assembly. EMBO J 2008;27(15):2077-2090
85. Smalla BG, Barone LR, Valentine JP, et al. A comparison between compound potency in an in vitro phospholipidosis assay and at the hERG-encoded potassium channel. J Pharmacol Toxicol Methods 2007;56(2):e70
86. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45 (Pubitemid 36351620)
87. S7B Nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. Washington, DC: FDA/Center for Drug Evaluation and Research, 2005. Available from: http://www.fda.gov/cder/ guidance/6885fnl.pdf. [Last accessed 29 April 2009]
88. Adams PC, Holt DW, Storey GCA, et al. Amiodarone and its desethyl metabolite: tissue distribution and morphological changes during long-term therapy. Circulation 1985;72(5):1064-1075
89. August C, Holzhausen HJ, Schmoldt A, et al. Histological and ultrastructural findings in chloroquine-induced cardiomyopathy. J Mol Med 1995;73:73-77
90. Costedoat-Chalumeau N, Hulot JS, Amoura Z, et al. Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology 2007;107(2):73-80 (Pubitemid 46272256)
91. Soong RT, Barouch LA, Champion HC, et al. New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy: a case report. Hum Pathol 2007;38(12):1858-1863 (Pubitemid 350179936)
92. Wang J, Wang H, Han H, et al. Phospholipid metabolite 1-palmitoyl-lysophosphatidylcholine enhances human ether-a-go-go-related gene (HERG) K+ channel function. Circulation 2001;104:2645-2648 (Pubitemid 33108127)
93. Bian JS, Kagan A, McDonald TV. Molecular analysis of PIP2 regulation of HERG and IKr. Am J Physiol Heart Circ Physiol 2004;287:H2154-63
94. Yan S, Chai H, Wang H, et al. Effects of lysophosphatidylcholine on monolayer cell permeability of human coronary artery endothelial cells. Surgery 2005;138(3):464-473 (Pubitemid 41415574)
95. Chapman H, Ramstrom C, Korhonen L, et al. Downregulation of the HERG (KCNH2)K+ channel by ceramide: evidence for ubiquitin-mediated lysosomal degradation. J Cell Sci 2005;118:5325-5334 (Pubitemid 41819594)
96. Casado E, Gratacós J, Tolosa C, et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis 2006;65:385-390 (Pubitemid 43268230)
97. Eadie MJ, Ferrier TM. Chloroquine myopathy. J Neurol Neurosurg Psychiatry 1966;29:331-337
98. Sghirlanzomi A, Mantegazza R, Mora M, et al. Chloroquine myopathy and myasthenia-like syndrome. Muscle Nerve 1988;11:114-119 (Pubitemid 18039609)
99. Schnellmann RG. Toxic responses of the kidney. Casarett & Doull's Toxicology: The basic science of poisons. Chapter 14. McGraw-Hill Medical Publishing Division, New York; 2001
100. Endre ZH, Westhuyzen J. Early detection of acute kidney injury: emerging new biomarkers. Nephrology 2008;13:91-98 (Pubitemid 351229631)
101. Emeigh Hart SG. Assessment of renal injury in vivo. J Pharmacol Toxicol Methods 2005;52:30-45
102. FDA, European Medicines Agency to consider additional test results when assessing new drug safety. FDA News. Washington, DC: FDA, 2008. Available from www.fda.gov/bbs/ topics/NEWS/2008/NEW01850.html. [Last accessed 17 September 2008]
103. Plaut ME, Schentag JJ, Jusko WJ. Aminoglycoside nephrotoxicity: comparative assessment in critically ill patients. J Med 1979;10(4):257-266 (Pubitemid 10198548)
104. Second meeting of the subcommittee of the expert committee on the selection and use of essential medicines: gentamicin ototoxicity in children. World Health Organization. Geneva, Switzerland: 2008. Available from: http://www.who.int/ selection-medicines/committees/ subcommittee/2/gentamicin- rev.pdf. [Last accessed 22 July 2009]
105. DeBroe ME, Paulus GJ, Verpooten GA, et al. Early effects of gentamicin, tobramycin, and amikacin on the human kidney. Kidney Int 1984;25:643-652
106. Gibey R, Dupond JL, Alber D, et al. Predictive value of urinary N-acetylbeta-D- glucosaminidase (NAG), alanine-aminopeptidase (AAP) and beta-2-microglobulin (beta2M) in evaluating nephrotoxicity of gentamicin. Clin Chim Acta 1981;116:25-34 (Pubitemid 11060000)
107. Hastings KL. Phospholipdiosis: is it a true toxicity? Presented at the Society of Toxicology Pathology (STP) Continuing Education Course on Drug-Induced Phospholipidosis; June 2008
108. Halstead BW, Zwickl CM, Morgan RE, et al. A clinical flow cytometry biomarker strategy: validation of pheripheral leukocyte phospholipidosis using Nile red. J Appl Toxicol 2006;26:169-177
109. Muller PY, Dieterle F. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. Expert Opin Drug Metab Toxicol 2009;5(9):1023-1038